{"id":389333,"date":"2022-12-16T00:00:00","date_gmt":"2022-12-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0003-2022-biopharma-migraine-disease-landscape-forecast-g7-2022\/"},"modified":"2026-04-26T23:27:43","modified_gmt":"2026-04-26T23:27:43","slug":"dlsfcg0003-2022-biopharma-migraine-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0003-2022-biopharma-migraine-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Migraine | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient\u2019s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP monoclonal antibodies for migraine prevention, oral CGRP receptor antagonists for both the treatment of acute migraine attacks and migraine prevention) and a range of innovative reformulations set for near-term launch in the United States, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost \/ coverage, and the headwinds posed by low-cost, early-line stand-of-care treatments will be key to the success of current and future players in migraine.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What events will shape the future of the acute \/ preventive and episodic \/ chronic market segments?<\/li>\n<li>How are the anti-CGRP monoclonal antibodies (e.g., Aimovig, Emgality) and oral gepants (i.e., Nurtec ODT \/ Vydura, Qulipta) being integrated into the generic-dominant migraine prophylaxis market? Which brands will be the most competitive and why?<\/li>\n<li>What is the dynamic between Ubrelvy and Nurtec ODT in the U.S. market? How are oral gepants being adopted into the triptan-dominant acute segment?<\/li>\n<li>How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research:<\/strong> 23 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Total, diagnosed, and drug-treated prevalent cases of episodic and chronic migraine, segmented by acute and prophylactic treatment.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase II: 7 drugs; Phase III \/ preregistration: 4 drugs.<\/p>\n<p><strong>Market forecast features: <\/strong>Patient-based market forecast extending through 2031, segmented by brands and generics.<\/p>\n<p><strong>Product Description: <\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement:<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, <em>Disease Landscape &#038; Forecast<\/em> introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389333","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-migraine","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389333\/revisions"}],"predecessor-version":[{"id":576165,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389333\/revisions\/576165"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}